July 1 China venture roundup: AZ co-leads $100M series B for Axbio

The China investment fund of AstraZeneca plc (LSE:AZN; NASDAQ:AZN) and Yunfeng Fund co-led a $100 million series B investment in Shenzhen-based sequencing company Axbio Inc., which will use the money to develop and commercialize its gene sequencing technology. Other investors in the series B were Cambridge Capital, SDIC China Merchants, and Wuyuan Capital. AstraZeneca established the fund with China International Capital Corp. Ltd. in 2019. 

Huashen Zhiyao Technology (Beijing) Co. Ltd. raised a RMB500 million ($74.8 million) series A financing, to develop its AI computing and drug development capabilities, expand its high-throughput experimental platforms, and undertake business development. The round was led by 5Y Capital, with participation from Gaorong Capital, Neumann Capital and three angel investors: Xianghe Capital, Hillhouse Capital and Qingzhi Capital...